2021/10/20  
Adimmune takes aim at vaccine contract manufacturing with MOU (2021/08/19)
其它新聞 Other News   
  • Taiwan’s legislative speaker says new ‘One China’ policy emerging in Washington
  • Japan and Taiwan’s ruling parties to hold security dialogue virtually
  • US offers booster shots to counter delta, CECC urged to do the same
  • CECC plans to nix dividers for families at restaurants
  • TRA, HSR add services over Mid-Autumn Festival holiday
  • 3% power price hike expected for big users including manufacturers
  • Printing expert turns business around by moving into disinfectant market
  • Wanted: two new zoo keepers for Kaohsiung’s Shoushan Zoo
  • Photography exhibition examines post-1930s Taiwanese culture
  • 英文 English 
    Adimmune takes aim at vaccine contract manufacturing with MOU (2021/08/19)

    Taiwanese biomedical firm Adimmune is positioning itself to win vaccine-making contracts from U.S. companies. On Thursday, it signed a memorandum of understanding with BD, a global medtech firm headquartered in the U.S. The two sides will collaborate to strengthen each other’s capabilities for vaccine contract manufacturing, or OEM. Adimmune plans to take aim at the American OEM market, winning orders from firms like Pfizer and Moderna.

    Adimmune has signed an MOU to become BD’s strategic partner in Asia. The two sides will help each other strengthen their OEM capabilities for vaccines. The goal is to win contracts from the U.S., where the OEM market is worth US$12 million annually.

    Chan Chi-hsien
    Adimmune CEO
    We want to develop capabilities for the vaccine-related industry, the upstream and downstream, the whole thing. We’re not limiting it to capabilities for COVID vaccines. Adimmune’s products and technologies are extremely diverse. COVID-19 vaccines are just one of our long-term projects, not all of them.

    Adimmune said that COVID shots are some of the vaccines the new partnership will target. To prepare for international contracts, it’s installed a new production line for pharmaceutical filling. It’s preparing to expand soon with additional lines.

    Albert Hung
    Adimmune
    Adimmune will try to secure as many orders as our production lines can handle. Of course, the Moderna vaccine and the Pfizer vaccine are both within that scope.

    Adimmune is currently working on developing its own COVID vaccine, though its progress has been outpaced by Medigen and United Biomedical. The firm hopes its partnership with BD will open up opportunities to make vaccines for international brands.

    中文 Chinese  
    國光生技攜手BD戰略合作 搶醫藥委託代工市場

    國光生技今天和美國BD公司,簽署合作備忘錄,董事長詹啟賢表示,希望藉此強化雙方在製藥、疫苗代工製造,也透露,接下來,將會爭取莫德納、BNT等疫苗廠的委託代工,搶攻每年1200億美元的委託代工市場。

    國光生技和美國BD公司簽署備忘錄,成為BD在亞洲的合作夥伴,希望強化雙方製藥、疫苗代工製造,搶攻每年1200億美金的委託代工市場。

    [[國光生技董事長 詹啟賢]]
    “疫苗相關產業,做上下游以及全方面發展,不只限於武漢肺炎疫苗,而且國光公司產品非常多元,技術也非常多元,武漢肺炎疫苗是我們長期發展的一部份,但不代表我們的全部”

    詹啟賢強調,武漢肺炎疫苗,依舊是國光,長期發展的一部分,而為了爭取國際代工,目前除了第二條充填線正式運轉,更準備第三、第四期的充填線。

    [[國光生技企業發展處處長 洪岳鵬]]
    “所有國光產線能足以支應的代工項目,國光都會努力去爭取,當然莫德納疫苗、BNT也在我們的範圍之內"

    以疫苗起家的國光,研發武漢肺炎疫苗,進度落後其他國產疫苗,如今透過和BD的合作,希望在疫苗代工領域,搶得先機。
    關於民視 常見問題 如何收看民視 意見信箱

    © 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
    地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

    本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。